Athira Pharma Names Rachel Lenington as CTO, Head of Product...

Athira Pharma Names Rachel Lenington as CTO, Head of Product Development Strategy

Healthcare Tech Outlook | Tuesday, June 22, 2021


Athira Pharma announces Rachel Lenington as the Chief Technology Officer, Head of Product Development Strategy. 

FREMONT, CA: Athira Pharma, Inc., a late clinical-stage biopharmaceutical firm dedicated to developing small molecules to restore neuronal health and prevent neurodegeneration, has announced Rachel Lenington as the Chief Technology Officer, Head of Product Development Strategy from June 14.

Ms. Lenington has over 20 years of biopharmaceutical leadership experience, with responsibilities encompassing R&D decision making, medication development and commercialization, and partnership management at leading companies such as Seagen Inc, the Bill & Melinda Gates Foundation, and Amgen.

"Rachel is adept at successfully integrating science and business, and I believe her unique skillset will be an asset to Athira and help guide our technical operations and integrated product strategy efforts," said Leen Kawas, Ph.D., President, and Chief Executive Officer at Athira. "We are excited to add Rachel to our executive team and look forward to her leadership as we continue to accelerate our innovative platform to treat neurodegenerative diseases."

Ms. Lenington added, "I am delighted to join Athiras dedicated efforts to discover and develop innovative therapies for neurodegeneration, with the ultimate goal of helping patients, caregivers and family members all over the world. I look forward to using my broad experience in leading portfolio strategy and operations to deliver on Athira's vision to make a positive difference for those in need of effective new treatment options."

Seagen Inc. most recently employed Ms. Rachel Lenington as Senior Vice President of Program and Portfolio Management. She oversaw a team responsible for strategic business operations, program, portfolio, and alliance management throughout her time at Seagen, and was essential during the organization's transformation into a worldwide, multi-product oncology company. 

Ms. Lenington formerly worked at the Bill & Melinda Gates Foundation as the Deputy Director, Strategy, Planning, and Management. She supervised strategy, business operations, and a multi-million-dollar yearly grant budget for special projects. Ms. Lenington previously spent ten years at Amgen, where she held positions of increasing responsibility, including Director, Global Program Manager. She managed a team of project management specialists responsible for Prolia's global development and commercialization. She started her career as a management consultant for Accenture and Deloitte Consulting, where she specialized in change management and ERP software implementation for Fortune 100 organizations.


Weekly Brief